WASHINGTON, Aug. 12 -- National Institutes of Health has issued a notice called: NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions.
The notice was published in the Federal Register on Aug. 12 by Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute.
Summary: Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in-class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform ...